Skip to content

Study · Randomized controlled trial · n = 6 · 1990

7 results

Peptide histidine valine: its haemodynamic actions and pharmacokinetics in man differ from those of vasoactive intestinal peptide and peptide histidine methionine.

Gill JS, Yiangou Y, Webb DJ, Meleagros L, Benjamin N, Chrysanthou BJ, Cockcroft JR, Causon RC, Camm AJ, Bloom SR

Clinical science (London, England : 1979)1 May 1990Cited by 3 (Europe PMC)

PMID2162275 (opens in a new tab)DOI10.1042/cs0780487 (opens in a new tab)PepBankPUB-02162275
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, intravenous VIP significantly increased heart rate.

    In plain wordsIn healthy volunteers, VIP given into a vein raised heart rate.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseHeart rate
    Study

    n = 6

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Vasoactive intestinal peptide given intravenously caused a significant increase in heart rate
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.
  2. 02HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, intravenous VIP significantly decreased diastolic blood pressure.

    In plain wordsIn healthy volunteers, VIP given into a vein lowered diastolic blood pressure.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n = 6

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Vasoactive intestinal peptide given intravenously caused a significant increase in heart rate and a decrease in diastolic, but not systolic, blood pressure
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.
  3. 03HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, intravenous VIP did not significantly change systolic blood pressure.

    In plain wordsIn healthy volunteers, VIP given into a vein did not change systolic blood pressure.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSystolic blood pressure
    Study

    n = 6

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Vasoactive intestinal peptide given intravenously caused a significant increase in heart rate and a decrease in diastolic, but not systolic, blood pressure
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.
  4. 04HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, local intra-arterial VIP infusion increased forearm blood flow.

    In plain wordsIn healthy volunteers, VIP infused into an artery of the forearm raised blood flow in the forearm.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseForearm blood flow
    Study

    n = 6

    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · intra-arterialAs given in this study (human).

    Source sentences

    Summary
    Forearm blood flow was increased by vasoactive intestinal peptide and peptide histidine valine when infused locally intra-arterially
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.
  5. 05HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, intravenous VIP infusion increased plasma cardiodilatin concentrations.

    In plain wordsIn healthy volunteers, VIP given into a vein raised blood levels of cardiodilatin, a heart hormone fragment.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma cardiodilatin
    Study

    n = 6

    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Plasma concentrations of cardiodilatin (the N-terminal peptide derived from pro-atrial natriuretic peptide) were increased by intravenous infusion of vasoactive intestinal peptide
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.
  6. 06HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, plasma adrenaline did not change during VIP infusion.

    In plain wordsIn healthy volunteers, blood adrenaline did not change during VIP infusion.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma adrenaline
    Study

    n = 6

    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Circulating plasma concentrations of adrenaline and noradrenaline did not change during infusion of vasoactive intestinal peptide, peptide histidine methionine or peptide histidine valine.
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.
  7. 07HumanRandomized controlled trialActivity measurement

    In six healthy volunteers, plasma noradrenaline did not change during VIP infusion.

    In plain wordsIn healthy volunteers, blood noradrenaline did not change during VIP infusion.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma noradrenaline
    Study

    n = 6

    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Circulating plasma concentrations of adrenaline and noradrenaline did not change during infusion of vasoactive intestinal peptide, peptide histidine methionine or peptide histidine valine.
    1 context sentence
    Summary · context
    The effects of intravenous and intra-arterial infusion of the peptides derived from prepro-vasoactive intestinal peptide, vasoactive intestinal peptide, peptide histidine methionine and peptide histidine valine, were examined in six healthy volunteers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.